Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer

被引：21

作者：

Mok, Tony S. K. ^{[1
]}

Lee, Kirsty ^{[1
]}

Leung, Linda ^{[1
]}

机构：

[1] Chinese Univ Hong Kong, Prince Wales Hosp, Sir YK Pau Canc Ctr, State Key Lab Sourthern China, Hong Kong, Hong Kong, Peoples R China

来源：

SEMINARS IN ONCOLOGY | 2014年 / 41卷 / 01期

关键词：

RANDOMIZED PHASE-II; TYROSINE KINASE INHIBITORS; PREVIOUSLY TREATED PATIENTS; ACQUIRED-RESISTANCE; OPEN-LABEL; 1ST-LINE TREATMENT; GENE-MUTATIONS; GEFITINIB; ERLOTINIB; CHEMOTHERAPY;

D O I：

10.1053/j.seminoncol.2013.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The epidermal growth factor receptor (EGFR) mutation is a potent oncogenic driver that accounts for carcinogenesis and tumor growth of pulmonary adenocarcinoma. Targeting EGFR with tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, progression-free survival (PFS), and quality of life. Multiple randomized studies have confirmed the superiority of EGFR TKIs over platinum-based chemotherapy and established EGFR TKIs as standard first-line therapy for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, almost all patients will develop resistance to EGFR TKIs and post progression therapy may include a combination of local therapy, systemic chemotherapy, and second-generation EGFR TKIs. (C) 2014 Elsevier Inc. All rights reserved.

引用

页码：101 / 109

页数：9

共 61 条

[1]

[Anonymous], ANN ONCOL

[2]

[Anonymous], J CLIN ONCOL S

[3]

[Anonymous], J CLIN ONCOL

[4]

[Anonymous], EUR J CANC

[5]

[Anonymous], ONCOLOGIST

[6] Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations [J].

Asami, Kazuhiro ;

Okuma, Tomohisa ;

Hirashima, Tomonori ;

Kawahara, Masaaki ;

Atagi, Shinji ;

Kawaguchi, Tomoya ;

Okishio, Kyoichi ;

Omachi, Naoki ;

Takeuchi, Naoko .

LUNG CANCER, 2013, 79 (03) :276-282

[7] Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer [J].

Butts, Charles A. ;

Bodkin, David ;

Middleman, Edward L. ;

Englund, Craig W. ;

Ellison, David ;

Alam, Yasmin ;

Kreisman, Harvey ;

Graze, Peter ;

Maher, James ;

Ross, Helen J. ;

Ellis, Peter M. ;

McNulty, William ;

Kaplan, Edward ;

Pautret, Virginie ;

Weber, Martin R. ;

Shepherd, Frances A. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) :5777-5784

[8] Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design [J].

Chaft, Jamie E. ;

Oxnard, Geoffrey R. ;

Sima, Camelia S. ;

Kris, Mark G. ;

Miller, Vincent A. ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2011, 17 (19) :6298-6303

[9]

COHEN S, 1965, DEV BIOL, V12, P394

[10] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

← 1 2 3 4 5 6 7 →